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Objectives: The antischistosomal properties of the marketed antiandrogens bicalutamide, flutamide, niluta-
mide and cyproterone acetate were studied both in vivo and in vitro.
Methods: Schistosoma mansoni-infected mice were treated orally with 50–400 mg/kg of the antiandrogens
3 and 7 weeks post-infection. In addition, three drug combinations of nilutamide and praziquantel (200/100,
100/100 and 100/50 mg/kg) were administered to mice harbouring adult S. mansoni. Drug effects were also
monitored in vitro following exposure to antiandrogen concentrations of 1, 10 and 100 mg/mL.
Results: Low total worm burden reductions (5%–37%) and low to moderate female worm burden reductions
(13%–75%) were achieved with the antiandrogens in the S. mansoni juvenile infection model. While flutamide
and cyproterone acetate lacked activity against adult S. mansoni in vivo, low to moderate total and female
worm burden reductions (0%–47%) were observed with bicalutamide. The highest total and female worm
burden reductions (85% and 71%, respectively) (P,0.001) were documented following a single 400 mg/kg
dose of nilutamide. Statistically significant total (91%) and female (85%) worm burden reductions were achieved
with the combination of nilutamide (200 mg/kg) and praziquantel (100 mg/kg). Schistosomes incubated with
100 mg/mL cyproterone acetate in vitro died after 15 h. Incubation with bicalutamide, nilutamide and flutamide
at 100 mg/mL resulted in decreased movement of S. mansoni adults.
Conclusions: Our data indicate that the hydantoin derivative nilutamide has interesting antischistosomal prop-
erties, confirming previous results of schistosomicidal activities of this drug class.
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Introduction
Schistosomiasis, caused by fluke worms of the genus
Schistosoma, continues to be an important cause of parasitic
morbidity and mortality, affecting.200 million individuals world-
wide, with a further 579 million living at risk of infection.1 Even
though praziquantel is an effective treatment for the chronic
stage of infection, it only has moderate activity against juvenile
schistosomes. In addition, drug resistance remains a concern;
hence, the development of novel treatment options is desirable.2,3
The schistosomicidal activities of hydantoins, such as
5,5-diphenylhydantoin (phenytoin), were described in the early
1950s. However, these drugs lacked oral activity and multiple
treatment courses were necessary in Schistosoma mansoni-
infected mice.4 In the early 1980s, a series of 3-arylhydantoins
were tested for their antischistosomal properties in the framework
of the antischistosomal drug discovery programme carried out by
Hoffmann–La Roche.5 Meta- and/or para-halogen-substituted
3-phenyl-5,5-dimethylhydantoins showed high antischistosomal
activities. For example, administration of a single 38 mg/kg
oral dose of 5,5-dimethyl-3-[4-fluoro-3-(trifluoromethyl)phe-
nyl]-2,4-imidazolidinedione (Ro 13-3978) resulted in a worm
burden reduction of 50% in mice harbouring adult S. mansoni.5
Nilutamide, a closely related 4-nitro-3-(trifluoromethyl)
phenylhydantoin derivative, and the structurally related tolui-
dides (flutamide and bicalutamide) are marketed antiandrogens
useful for the treatment of metastatic prostate cancer. These
drugs block the binding of testosterone and dihydrotestosterone
at the androgen receptor.6
The aim of this study was to elucidate the antischistosomal
properties of bicalutamide, flutamide and nilutamide in vitro
and in mice harbouring juvenile and adult S. mansoni. Cyproter-
one acetate, a structurally unrelated steroidal antiandrogen, was
included as a control.
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Materials and methods
Drugs
Bicalutamide, flutamide, nilutamide and cyproterone acetate (Figure 1)
were purchased from Sigma–Aldrich. All drugs were suspended in 7%
(v/v) Tween 80% and 3% (v/v) ethanol shortly before oral treatment of
mice (10 mL/kg). For the in vitro studies, stock solutions of 10 mg/mL
were prepared in DMSO (Fluka, Buchs, Switzerland).
Animals and parasites
In vivo studies were carried out in accordance with Swiss animal welfare
regulations. This work was carried out under licences granted by the Can-
tonal Veterinary Office, Basel Stadt. Female mice (NMRI strain, n¼165,
weight 20–22 g) were purchased from Harlan (Horst, The Netherlands),
maintained under environmentally controlled conditions and acclimat-
ized for 1 week before infection. Cercariae of S. mansoni were obtained
from infected Biomphalaria glabrata maintained in our laboratories, as
described previously.3
In vivo studies
Each mouse was infected subcutaneously with 80 S. mansoni cercariae.
Twenty-one days (pre-patent infection) and 49 days (patent infection)
after infection, groups of five mice were treated orally with the antiandro-
gens (single doses of 50–400 mg/kg). For the combination chemotherapy
experiments, groups of mice were treated with praziquantel monother-
apy (50 and 100 mg/kg) or combinations of nilutamide and praziquantel
(200 mg/kg nilutamide plus 100 mg/kg praziquantel, 100 mg/kg niluta-
mide plus 100 mg/kg praziquantel and 100 mg/kg nilutamide plus
50 mg/kg praziquantel). Four groups of eight or nine untreated mice
served as controls.
At 21 days post-treatment, animals were killed by the CO2 method,
dissected and worms were sexed and counted, as described in previous
publications.3
In vitro studies
Two male and two female schistosomes were placed in each well of a
48-well plate containing RPMI 1640 culture medium supplemented
with 5% fetal calf serum, 100 U/mL penicillin and 100 mg/mL streptomy-
cin. Concentrations of 100, 10 or 1 mg/mL of the drugs were added.
Schistosomes incubated with 0.1% DMSO served as controls. Worms
were kept in an incubator at 378C and 5% CO2 for up to 66 h. Worm
motility, phenotypic changes and death were recorded shortly after
drug exposure and at 15, 22, 45 and 66 h post-incubation. Each assay
was carried out in duplicate.
Statistical analysis
The Kruskal–Wallis (KW) test was used to compare the medians of the
worm burdens in the treatment and control groups or in the monother-
apy versus combination chemotherapy treatment groups (version 2.4.5
Statsdirect, Cheshire, UK). The significance level was P≤0.05.
Results
In vitro findings
In the presence of antiandrogen concentrations of 1 and
10 mg/mL, no effect was observed on the viability and
morphology of adult schistosomes.
Schistosomes incubated with 100 mg/mL cyproterone acetate
died after 15 h. Incubation with 100 mg/mL bicalutamide,
nilutamide and flutamide resulted in decreased movement of
S. mansoni adults; however, schistosomes were still alive after
66 h and no morphological changes were observed.
Dose–response relationships of antiandrogens against
juvenile S. mansoni
Total worm burden reductions of 5.1%–35.6% (P.0.05) were
achieved with nilutamide. The highest female worm burden
reduction of 75.4% was observed with a 200 mg/kg dose of
nilutamide, while moderate female worm burden reductions of
22.5%–27.5% were observed following 50, 100 and 400 mg/kg
nilutamide doses. The female worm burden reductions in
nilutamide-treated mice were statistically significant
(KW¼4.15, P¼0.042). In contrast, flutamide effected only low
total and female worm burden reductions of 3.7%–27.5%
(P.0.05). Similarly, administration of 100–400 mg/kg bicaluta-
mide to mice infected with juvenile S. mansoni resulted in stat-
istically insignificant total and female worm burden reductions
of 17.3%–46.4%. A 400 mg/kg dose of cyproterone acetate
achieved low, statistically insignificant, total and female worm
burden reductions of 10.2% and 12.9%, respectively (Table 1).
Dose–response relationships of antiandrogens against
adult S. mansoni
At 50 mg/kg, nilutamide showed no effect on adult schisto-
somes. Moderate worm burden reductions (30.7%–49.6%)
were observed with doses of 100 and 200 mg/kg. At 400 mg/kg,
nilutamide reduced total and female worm burdens by 84.8%
and 71.3%, respectively. The total (KW¼6.78, P¼0.001) and
female (KW¼11.38, P¼0.0007) worm burden reductions in the
nilutamide-treated mice were statistically highly significant. No
effects on female and total adult worm burdens were observed
for flutamide at any dose tested. Bicalutamide at 100 mg/kg
failed to show schistosomicidal activity, although higher doses
of 200–400 mg/kg showed moderate (35.4%–47.0%) total
and female worm burden reductions; however, these were not
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Figure 1. Chemical structures of flutamide, nilutamide, bicalutamide and
cyproterone acetate.
Keiser et al.
1992
statistically significant. Cyproterone acetate given at 400 mg/kg
had no effect on worm burden (Table 1).
Combinations of nilutamide plus praziquantel against
adult S. mansoni in vivo
Low total worm burden reductions of 16.0% and 17.8% were
achieved with praziquantel at 50 or 100 mg/kg, respectively. Combi-
nations of nilutamide (100 mg/kg) and praziquantel (50 or 100 mg/
kg) revealed an increase in worm survival, above the level observed
with praziquantel or nilutamide monotherapy. However, a combi-
nation of nilutamide (200 mg/kg) and praziquantel (100 mg/kg)
produced statistically significant total (90.6%; P¼0.013) and
female (85.1%; P¼0.018) worm burden reductions (Table 2).
Discussion
Identification of marketed drugs as antischistosomals stream-
lines drug development, which can be accomplished with relative
speed and economy.7
In this study, we examined the schistosomicidal activities of
single oral doses of selective androgen receptor antagonists in
mice, one steroid (cyproterone acetate) and three non-steroidal
antiandrogens (bicalutamide, flutamide and nilutamide),
Table 1. Effect on worm burden of four antiandrogens administered as single oral doses ranging from 50 to 400 mg/kg to mice harbouring a 21- or
49-day-old S. mansoni infection
Infection Drug
Dose (mg/kg)
(single)
Mean number
of worms (SD)
Total worm burden
reduction (%) P value
Female worm burden
reduction (%) P valuetotal females
— Control 1 — 27.4 (10.9) 13.8 (5.6) — — — —
Control 2 — 25.3 (9.5) 12.0 (2.8) — — — —
Control 3 — 27.0 (12.6) 11.6 (7.4) — — — —
Control 4 — 25.6 (5.0) 12.4 (3.3) — — — —
Juvenile infection nilutamide 50a 24.4 (8.4) 10.0 (3.3) 11.0 0.189 27.5 0.042
100a 26.0 (8.3) 10.2 (3.8) 5.1 26.1
200a 21.4 (5.1) 3.4 (1.5) 21.9 75.4
400b 16.3 (12.7) 9.3 (6.7) 35.6 22.5
flutamide 50a 25.8 (7.3) 12.0 (4.1) 5.8 0.324 13.1 0.151
100a 20.8 (11.1) 10.0 (4.5) 24.1 27.5
200a 26.4 (4.1) 11.8 (3.6) 3.7 14.5
bicalutamide 100a 17.4 (8.1) 7.4 (3.6) 36.5 0.022 46.4 0.092
200c 21.4 (12.4) 9.6 (6.8) 20.8 17.3
400c 18.6 (6.3) 9.2 (3.9) 31.1 36.2
cyproterone acetate 400d 23.0 (10.1) 10.8 (4.6) 10.2 0.502 12.9 0.543
Adult infection nilutamide 50a,e 30.0 (6.1) 12.8 (3.0) 0 0.001 7.3 0.0007
100a 19.0 (4.3) 8.0 (2.3) 30.7 42.0
200a,f 13.8 (4.5) 7.0 (2.2) 49.6 49.3
400b,g 5.5 (2.5) 5.0 (2.4) 84.8 71.3
flutamide 50a .27 .14 0 ND 0 ND
100a .27 .14 0 0
200a,h 31.7 (6.7) 15.7 (3.2) 0 0
bicalutamide 100a 30.8 (5.3) 12.8 (3.8) 0 0.148 7.2 0.131
200c 14.3 (8.0) 7.5 (4.6) 47.0 35.4
400c,i 16.0 (4.1) 6.5 (1.3) 40.8 44.0
cyproterone acetate 400d 32.2 (7.6) 16.2 (3.7) 0 ND 0 ND
ND, not done.
aVersus Control 1.
bVersus Control 2.
cVersus Control 3.
dVersus Control 4.
eOne mouse died 20 days post-treatment.
fOne mouse died 3 days post-treatment.
gOne mouse died 1 day post-treatment.
hOne mouse died 14 days post-treatment.
iOne mouse died 6 days post-treatment.
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marketed for the treatment of male hypogonadism, muscle
wasting, anaemia, benign prostate hyperplasia and prostate
cancer.6 Androgen receptor modulators are often associated
with adverse events, such as hepatotoxicity, flushing and loss
of libido or virilizing effects, since multiple doses for several
months are necessary for treatment of these serious con-
ditions.6,8 The rationale for selecting these compounds for
testing against S. mansoni arose from the striking structural simi-
larity of the hydantoins nilutamide and Ro 13-3978, the latter of
which has potent antischistosomal activity in rodent models.5
A high total worm burden reduction (85%) was achieved
with nilutamide at 400 mg/kg against adult S. mansoni,
confirming the interesting antischistosomal properties of this
structural class, in particular of the trifluoromethyl-substituted
3-arylhydantoins.5 However, the 4-nitro-3-(trifluoromethyl)
phenyl-substituted nilutamide is much less effective than
the 4-fluoro-3-(trifluoromethyl)phenyl-substituted Ro 13-3978,
the latter of which has a reported ED50 of 38 mg/kg in the
S. mansoni mouse model.5
Disappointingly, nilutamide achieved only low worm burden
reductions against juvenile S. mansoni in vivo. High worm
burden reductions observed against all development stages of
schistosomes would be a valuable attribute of a new antischisto-
somal drug and an important differentiation from praziquantel.
Praziquantel is characterized by only moderate activity against
juvenile schistosomes, requiring frequent retreatment of patients
to remove the schistosome burden of the continuously develop-
ing adult worms.2
Since drug combinations can enhance therapeutic effects and
reduce adverse events, we studied nilutamide/praziquantel com-
binations. Simultaneous administration of nilutamide (200 mg/
kg) and praziquantel (100 mg/kg) resulted in high worm burden
reductions, suggesting an additive effect of the drugs. Interest-
ingly, when the nilutamide dose was lowered further (100 mg/
kg), a high worm survival, above the level seen with praziquantel
and nilutamide monotherapy, was observed.
While cyproterone acetate and flutamide lacked activity in
mice harbouring adult S. mansoni, moderate activities were
observed with bicalutamide at doses of ≥200 mg/kg. Variations
in the interaction with the androgen receptors might play a
role in the difference in the antischistosomal activities observed
among the four drugs tested. Indeed, cortisol and dehydroepian-
drosterone have been reported to have a profound effect on the
growth and survival of schistosomes, and hence the onset,
establishment and pathogenesis of schistosomiasis.9 Classical
nuclear receptors for steroids have been identified in schisto-
somes.9 The varying affinities of these drugs for androgen recep-
tors in vitro and in vivo10 might also partially explain the
differences in the antischistosomal properties observed in our
in vitro and in vivo studies.
In conclusion, high in vivo schistosomicidal activity was
observed for single oral doses of the marketed antiandrogen
drug nilutamide. It would be worthwhile to investigate further
analogues of this molecule that have been synthesized over
the past years or that have even already emerged as leads,
such as BMS564929.6
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Table 2. Effect on worm burden of praziquantel/nilutamide combinations given to mice harbouring a 49-day-old S. mansoni infection
Treatment Drug
Dose (mg/kg)
(single)
Mean number of
worms (SD)
Total worm burden
reduction (%)
P
value
Female worm burden
reduction (%)
P
valuetotal females
— Control 2 — 25.3 (9.5) 12.0 (2.8) — — — —
Control 4 — 25.6 (5.0) 12.4 (3.3) — — — —
Monotherapy praziquantel 50a 21.5 (10.5) 11.5 (7.2) 16.0 0.164 7.3 0.138
praziquantel 100a 21.0 (9.5) 9.5 (3.8) 17.8 0.344 23.4 0.311
nilutamide 100b 19.0 (4.3) 8.0 (2.3) 30.7 0.06 42.0 0.027
nilutamide 200b 13.8 (4.5) 7.0 (2.2) 49.6 0.008 49.3 0.01
Combination
chemotherapy
nilutamide plus
praziquantel
200/100c 3.4 (3.2) 2.6 (1.5) 90.6 0.013 85.1 0.018
100/100d 24.8 (10.0) 13.0 (4.7) 3.1 0.389 0 ND
100/50d 22.6 (11.2) 11.0 (4.3) 11.7 0.753 11.3 0.293
ND, not done.
aVersus Control 4.
bVersus Control 2.
cVersus nilutamide 200 mg/kg.
dVersus nilutamide 100 mg/kg.
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